NCT02561273 - Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

November 1, 2019

Study Completion Date

November 1, 2020

Conditions

Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveHepatosplenic T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedStage II Angioimmunoblastic T-cell LymphomaStage II Enteropathy-Associated T-Cell LymphomaStage III Angioimmunoblastic T-cell LymphomaStage III Enteropathy-Associated T-Cell LymphomaStage IV Angioimmunoblastic T-cell LymphomaStage IV Enteropathy-Associated T-Cell Lymphoma

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous stem cell transplant

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo peripheral blood stem cell transplant

DRUG

Prednisone

Given PO

DRUG

Vincristine Sulfate

Given IV

Trial Locations (8)

10065

Memorial Sloan-Kettering Cancer Center, New York

30322

Emory University/Winship Cancer Institute, Atlanta

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

68198

University of Nebraska Medical Center, Omaha

80045

University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora

91010

City of Hope Comprehensive Cancer Center, Duarte

94304

Stanford Cancer Institute, Palo Alto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER